BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Man RJ, Chen LW, Zhu HL. Telomerase inhibitors: a patent review (2010-2015). Expert Opin Ther Pat 2016;26:679-88. [PMID: 27104627 DOI: 10.1080/13543776.2016.1181172] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 2016;4:79. [PMID: 27503138 DOI: 10.1186/s40478-016-0351-2] [Cited by in Crossref: 112] [Cited by in F6Publishing: 111] [Article Influence: 18.7] [Reference Citation Analysis]
2 Culletta G, Allegra M, Almerico AM, Restivo I, Tutone M. In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity. Pharmaceuticals 2022;15:82. [DOI: 10.3390/ph15010082] [Reference Citation Analysis]
3 Pesenti C, Paganini L, Fontana L, Veniani E, Runza L, Ferrero S, Bosari S, Menghi M, Marfia G, Caroli M, Silipigni R, Guerneri S, Tabano S, Miozzo M. Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status. Oncotarget 2017;8:57134-48. [PMID: 28915660 DOI: 10.18632/oncotarget.19103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
4 Dubik N, Mai S. Lamin A/C: Function in Normal and Tumor Cells. Cancers (Basel) 2020;12:E3688. [PMID: 33316938 DOI: 10.3390/cancers12123688] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Dogan F, Biray Avci C. Correlation between telomerase and mTOR pathway in cancer stem cells. Gene 2018;641:235-9. [DOI: 10.1016/j.gene.2017.09.072] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
6 Morais KS, Guimarãesb AFR, Ramos DAR, Silva FP, de Oliveira DM. Long-term exposure to MST-312 leads to telomerase reverse transcriptase overexpression in MCF-7 breast cancer cells. Anticancer Drugs 2017;28:750-6. [PMID: 28520570 DOI: 10.1097/CAD.0000000000000508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ma S, Rudra S, Campian JL, Dahiya S, Dunn GP, Johanns T, Goldstein M, Kim AH, Huang J. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv 2020;2:vdaa126. [PMID: 33235995 DOI: 10.1093/noajnl/vdaa126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Morais KDS, Arcanjo DDS, Faria Lopes GP, Silva GG, Mota THA, Gabriel TR, Rabello Ramos DDA, Silva FP, Oliveira DM. Long‐term in vitro treatment with telomerase inhibitor MST‐312 induces resistance by selecting long telomeres cells. Cell Biochem Funct 2019;37:273-80. [DOI: 10.1002/cbf.3398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Liu MY, Nemes A, Zhou QG. The Emerging Roles for Telomerase in the Central Nervous System. Front Mol Neurosci 2018;11:160. [PMID: 29867352 DOI: 10.3389/fnmol.2018.00160] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
10 Günes C, Wezel F, Southgate J, Bolenz C. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat Rev Urol 2018;15:386-93. [PMID: 29599449 DOI: 10.1038/s41585-018-0001-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
11 Bousali M, Karamitros T. Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma. Microorganisms 2022;10:253. [DOI: 10.3390/microorganisms10020253] [Reference Citation Analysis]
12 Lee HS, Carmena M, Liskovykh M, Peat E, Kim JH, Oshimura M, Masumoto H, Teulade-Fichou MP, Pommier Y, Earnshaw WC, Larionov V, Kouprina N. Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy. Cancer Res 2018;78:6282-96. [PMID: 30166419 DOI: 10.1158/0008-5472.CAN-18-0894] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
13 Fragkiadaki P, Renieri E, Kalliantasi K, Kouvidi E, Apalaki E, Vakonaki E, Mamoulakis C, Spandidos DA, Tsatsakis A. Τelomerase inhibitors and activators in aging and cancer: A systematic review. Mol Med Rep 2022;25:158. [PMID: 35266017 DOI: 10.3892/mmr.2022.12674] [Reference Citation Analysis]
14 Cimino-Reale G, Gandellini P, Santambrogio F, Recagni M, Zaffaroni N, Folini M. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. J Hematol Oncol 2017;10:140. [PMID: 28716051 DOI: 10.1186/s13045-017-0510-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
15 Wen L, Zhao C, Song J, Ma L, Ruan J, Xia X, Chen YE, Zhang J, Ma PX, Xu J. CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells. Int J Mol Sci 2020;21:E653. [PMID: 31963842 DOI: 10.3390/ijms21020653] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Liu Y, Li Z, Tang X, Li M, Shi F. Association between hTERT Polymorphisms and Female Papillary Thyroid Carcinoma. Recent Pat Anticancer Drug Discov 2019;14:268-79. [PMID: 31538903 DOI: 10.2174/1574892814666190919145453] [Reference Citation Analysis]
17 Baginski M, Serbakowska K. In silico design of telomerase inhibitors. Drug Discov Today 2020;25:1213-22. [PMID: 32387261 DOI: 10.1016/j.drudis.2020.04.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. TERT-Regulation and Roles in Cancer Formation. Front Immunol 2020;11:589929. [PMID: 33329574 DOI: 10.3389/fimmu.2020.589929] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Vasko T, Kaifie A, Stope MB, Kraus T, Ziegler P. Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions. Int J Mol Sci 2017;18:E2267. [PMID: 29143804 DOI: 10.3390/ijms18112267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
20 Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci 2019;110:2247-57. [PMID: 31099446 DOI: 10.1111/cas.14067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]